医学
肿瘤科
化疗
内科学
肺癌
癌症
临床试验
疾病
呼吸道疾病
化疗方案
放射治疗
梅德林
免疫疗法
标识
DOI:10.26855/ijcemr.2026.05.015
摘要
Objective: Taking the clinical treatment of advanced non-small cell lung cancer (NSCLC) as the research starting point, this study explores the practical application value of sintilimab combined with chemotherapy. Methods: The study was conducted from December 2024 to December 2025. A total of 86 NSCLC pa-tients at stage ⅢB-Ⅳ were selected from our hospital and randomly divided into two groups. The reference group (43 patients) received conventional chemotherapy, while the observation group (43 patients) received sintilimab in addition to the chemotherapy. After four treatment cycles, the clinical efficacy, serum tumor marker levels, and safety were compared between the two groups. Results: The objective response rate (ORR) and disease control rate (DCR) in the observation group were significantly higher than those in the reference group (P < 0.05). The levels of neuron-specific enolase (NSE), carbohydrate antigen 19-9 (CA19-9), and squamous cell carcinoma-related antigen (SCC-Ag) in the observation group were significantly lower than those in the reference group (P < 0.05). There was no significant difference in chemotherapy-related hematological and gastrointestinal adverse reactions between the two groups (P > 0.05). Conclusion: Based on the actual situation of patients with stage ⅢB-Ⅳ advanced NSCLC, combining sintilimab with platinum-based double-drug chemotherapy can significantly improve clinical efficacy, reduce tumor marker levels, and has controllable safety, making it worthy of promotion.
科研通智能强力驱动
Strongly Powered by AbleSci AI